Log in

NASDAQ:CRTXCortexyme Stock Price, Forecast & News

$38.80
+3.87 (+11.08 %)
(As of 04/7/2020 04:14 AM ET)
Add
Compare
Today's Range
$35.56
Now: $38.80
$42.19
50-Day Range
$29.01
MA: $45.52
$72.51
52-Week Range
$19.35
Now: $38.80
$73.84
Volume220,700 shs
Average Volume158,453 shs
Market Capitalization$1.14 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.76 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryHealth Care Technology
SectorMedical
Current SymbolNASDAQ:CRTX
CUSIP21924P10
Phone415-910-5717

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.30 per share

Profitability

Net Income$-36,980,000.00

Miscellaneous

Employees16
Market Cap$1.14 billion
Next Earnings Date6/10/2020 (Estimated)
OptionableNot Optionable

Receive CRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter.


Cortexyme (NASDAQ:CRTX) Frequently Asked Questions

How has Cortexyme's stock been impacted by COVID-19 (Coronavirus)?

Cortexyme's stock was trading at $37.02 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CRTX stock has increased by 4.8% and is now trading at $38.80. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cortexyme?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cortexyme in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Cortexyme.

When is Cortexyme's next earnings date?

Cortexyme is scheduled to release its next quarterly earnings announcement on Wednesday, June 10th 2020. View our earnings forecast for Cortexyme.

How were Cortexyme's earnings last quarter?

Cortexyme, Inc. (NASDAQ:CRTX) issued its quarterly earnings data on Tuesday, March, 17th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by $0.06. View Cortexyme's earnings history.

What price target have analysts set for CRTX?

3 brokerages have issued twelve-month price targets for Cortexyme's shares. Their forecasts range from $14.00 to $53.00. On average, they expect Cortexyme's share price to reach $34.25 in the next twelve months. This suggests that the stock has a possible downside of 11.7%. View analysts' price targets for Cortexyme.

Has Cortexyme been receiving favorable news coverage?

News coverage about CRTX stock has trended very negative this week, according to InfoTrie. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cortexyme earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutCortexyme.

Who are some of Cortexyme's key competitors?

What other stocks do shareholders of Cortexyme own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cortexyme investors own include Honeywell International (HON), Alibaba Group (BABA), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T), Thermo Fisher Scientific (TMO), Verizon Communications (VZ), Home Depot (HD), Johnson & Johnson (JNJ) and Pfizer (PFE).

Who are Cortexyme's key executives?

Cortexyme's management team includes the following people:
  • Ms. Casey C. Lynch, Co-Founder, Chairman, Pres & CEO (Age 45)
  • Mr. Stephen S. Dominy, Co-Founder, Chief Scientific Officer & Director (Age 63)
  • Ms. Kristen Gafric, Co-Founder, Sr. VP of Legal & Admin. and Sec. (Age 43)
  • Mr. Christopher P. Lowe, CFO & Treasurer (Age 48)
  • Dr. Michael J. Detke, Chief Medical Officer (Age 52)

When did Cortexyme IPO?

(CRTX) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

What is Cortexyme's stock symbol?

Cortexyme trades on the NASDAQ under the ticker symbol "CRTX."

How do I buy shares of Cortexyme?

Shares of CRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cortexyme's stock price today?

One share of CRTX stock can currently be purchased for approximately $38.80.

How big of a company is Cortexyme?

Cortexyme has a market capitalization of $1.14 billion. The biopharmaceutical company earns $-36,980,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. Cortexyme employs 16 workers across the globe. View additional information about Cortexyme.

What is Cortexyme's official website?

The official website for Cortexyme is http://www.cortexyme.com/.

How can I contact Cortexyme?

Cortexyme's mailing address is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 415-910-5717 or via email at [email protected]

This page was last updated on 4/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel